We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CCAAT Enhancer-binding Protein Alpha (CEBPA) Gene Expression in a Cohort of Turkish Patients with Multiple Myeloma.
- Authors
KABASAKAL, Tuba; AY, Mustafa Ertan; ÇEVİK, Kenan; TOMBAK, Anıl; İZCİ AY, Özlem; ERDAL, Mehmet Emin
- Abstract
OBJECTIVE: Hematopoiesis is regulated and maintained by the function of the particular transcription factors. CCAAT enhancer-binding protein alpha (CEBPA), an important transcription factor, has a part in the regulation of cell cycle, granulocytic differentiation, and more. The possible role of CEBPA in multiple myeloma (MM) development has not been clarified so far. Therefore, this study aimed to explore the relationship between the expression levels of the CEBPA gene in Turkish patients diagnosed with MM. METHODS: Using quantitative real-time PCR, the expression level of the CEBPA gene was examined in the bone marrow samples of 44 MM patients and 13 healthy controls. Statistical analyses were performed using SPSS, 13.3.1, and p<0.05 was evaluated as statistical significance level. RESULTS: Although there was a decrease CEBPA expression levels in the patient group compared to the control group, no statistically significant relationship was found in terms of CEBPA gene expression level and MM compared with the controls (p=0.436). CONCLUSION: Our findings suggest that the change in the expression level of CEBPA transcript itself has probably no effect in the pathogenesis of MM patients, although it is an important problem that needs further researches with large-scale samples.
- Subjects
TURKEY; STATISTICAL significance; QUANTITATIVE research; GENE expression; CANCER patients; DESCRIPTIVE statistics; MULTIPLE myeloma; TRANSCRIPTION factors; POLYMERASE chain reaction; BONE marrow; DATA analysis software; CARRIER proteins; LONGITUDINAL method
- Publication
Turkish Journal of Oncology / Türk Onkoloji Dergisi, 2022, Vol 37, Issue 1, p41
- ISSN
1300-7467
- Publication type
Article
- DOI
10.5505/tjo.2021.2825